To evaluate the use of intermittently scanned continuous glucose monitoring (isCGM) in patients with liver cirrhosis (LC).
Methods:
Observational study including 30 outpatients with LC (Child-Pugh B/C): 10 without diabetes (DM) (G1), 10 with newly diagnosed DM by oral glucose tolerance test (G2), and 10 with a previous DM diagnosis (G3). isCGM (FreeStyle Libre Pro) was used for 56 days (four sensors/patient). Blood tests were performed at baseline and after 28 and 56 days.
Results:
No differences were found in the baseline characteristics, except for higher age in G3. There were significant differences between G1, G2 and G3 in glucose management indicator (GMI) (5.28 ± 0.17, 6.03 ± 0.59, 6.86 ± 1.08%, P < .001), HbA1c (4.82 ± 0.39, 5.34 ± 1.26, 6.97 ± 1.47%, P < .001), average glucose (82.79 ± 7.06, 113.39 ± 24.32, 149.14 ± 45.31mg/dL, P < .001), time in range (TIR) (70.89 ± 9.76, 80.2 ± 13.55, 57.96 ± 17.96%, P = .006), and glucose variability (26.1 ± 5.0, 28.21 ± 5.39, 35.31 ± 6.85%, P = .004). There was discordance between GMI and HbA1c when all groups were considered together, with a mean difference of 0.35% (95% SD 0.17, 0.63). In G1, the mean difference was 0.46% (95% SD 0.19, 0.73) and in G2 0.69% (95% SD 0.45, 1.33). GMI and HbA1c were concordant in G3, with a mean difference of −0.10 % (95% SD [−0.59, 0.38]).
Conclusion:
Disagreements were found between the GMI and HbA1c levels in patients with LC. isCGM was able to detect abnormalities in glycemic control that would not be detected by monitoring with HbA1c, suggesting that isCGM can be useful in assessing glycemic control in patients with LC.
PicardiAD’AvolaDGentilucciUV, et al. Diabetes in chronic liver disease: from old concepts to new evidence. Diabetes Metab Res Rev. 2006;22(4):274-283. https://onlinelibrary.wiley.com/doi/10.1002/dmrr.636. Accessed August 16, 2022.
2.
KishimotoMNodaM. Verification of glycemic profiles using continuous glucose monitoring: cases with steroid use, liver cirrhosis, enteral nutrition, or late dumping syndrome. J Med Invest. 2015;62(1-2):1-10. https://www.jstage.jst.go.jp/article/jmi/62/1.2/62_1/_article. Accessed August 16, 2022.
ElkriefLRautouPESarinSVallaDParadisVMoreauR. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int. 2016;36(7):936-948. http://doi.wiley.com/10.1111/liv.13115. Accessed February 22, 2019.
5.
García-CompeánDJáquez-QuintanaJOLavalle-GonzálezFJ, et al. The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis. A prospective study. Ann Hepatol. 2012;11(2):240-248.
6.
Garcia-CompeanDJaquez-QuintanaJOGonzalez-GonzalezJAMaldonado-GarzaH. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol. 2009;15(3):280. http://www.wjgnet.com/1007-9327/full/v15/i3/280.htm. Accessed April 22, 2021.
7.
LiuTLTrogdonJWeinbergerMFriedBBarrittAS4th. Diabetes is associated with clinical decompensation events in patients with cirrhosis. Dig Dis Sci. 2016;61(11):3335-3345. http://link.springer.com/10.1007/s10620-016-4261-8. Accessed August 16, 2022.
NadelsonJSatapathySKNairS. Glycated hemoglobin levels in patients with decompensated cirrhosis. Int J Endocrinol. 2016;2016:8390210. https://www.hindawi.com/journals/ije/2016/8390210/. Accessed July 10, 2022.
11.
KogaMKasayamaSKaneharaHBandoY. CLD (chronic liver diseases)-HbA1C as a suitable indicator for estimation of mean plasma glucose in patients with chronic liver diseases. Diabetes Res Clin Pract. 2008;81(2):258-262. https://linkinghub.elsevier.com/retrieve/pii/S0168822708001940. Accessed February 16, 2019.
12.
WrightLAHirschIB. Metrics beyond hemoglobin A1C in diabetes management: time in range, hypoglycemia, and other parameters. Diabetes Technol Ther. 2017;19(suppl 2):S16-S26. http://www.liebertpub.com/doi/10.1089/dia.2017.0029. Accessed February 16, 2019.
DunnTCXuYHayterGAjjanRA. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: a European analysis of over 60 million glucose tests. Diabetes Res Clin Pract. 2018;137:37-46. https://linkinghub.elsevier.com/retrieve/pii/S016882271731104X. Accessed August 16, 2022.
HaakTHanaireHAjjanRHermannsNRivelineJPRaymanG. Use of flash glucose-sensing technology for 12 months as a replacement for blood glucose monitoring in insulin-treated type 2 diabetes. Diabetes Ther. 2017;8(3):573-586. http://link.springer.com/10.1007/s13300-017-0255-6. Accessed October 10, 2019.
19.
Ish-ShalomMWainsteinJRazIMosenzonO. Improvement in glucose control in difficult-to-control patients with diabetes using a novel flash glucose monitoring device. J Diabetes Sci Technol. 2016;10(6):1412-1413. http://journals.sagepub.com/doi/10.1177/1932296816653412. Accessed August 16, 2022.
BaileyTBodeBWChristiansenMPKlaffLJAlvaS. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther. 2015;17(11):787-794. http://www.liebertpub.com/doi/10.1089/dia.2014.0378. Accessed February 23, 2019.
22.
Al HayekAARobertAAAl DawishMA. Differences of freestyle libre flash glucose monitoring system and finger pricks on clinical characteristics and glucose monitoring satisfactions in type 1 diabetes using insulin pump. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419861102. http://journals.sagepub.com/doi/10.1177/1179551419861102. Accessed August 16, 2022.
LuJYingZWangPFuMHanCZhangM. Effects of continuous glucose monitoring on glycaemic control in type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024;26(1):362-372. https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15328. Accessed January 17, 2024.
25.
TeoEHassanNTamWKohS. Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis. Diabetologia. 2022;65(4):604-619. https://link.springer.com/10.1007/s00125-021-05648-4. Accessed Jan 12, 2024.
26.
OwenOETrappVEReichardGAJr, et al. Nature and quantity of fuels consumed in patients with alcoholic cirrhosis. J Clin Invest. 1983;72(5):1821-1832. http://www.jci.org/articles/view/111142. Accessed February 17, 2019.
BattelinoTDanneTBergenstalRM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593-1603. http://care.diabetesjournals.org/lookup/doi/10.2337/dci19-0028. Accessed November 20, 2021.
37.
KlonoffDCWangJRodbardD, et al. A glycemia risk index (GRI) of hypoglycemia and hyperglycemia for continuous glucose monitoring validated by clinician ratings. J Diabetes Sci Technol. 2023;17(5):1226-1242.
DunnTCXuYBergenstalRMOgawaWAjjanRA. Personalized glycated hemoglobin in diabetes management: closing the gap with glucose management indicator. Diabetes Technol Ther. 2023;25(suppl 3):S65-S74. https://www.liebertpub.com/doi/10.1089/dia.2023.0146. Accessed January 12, 2024.
40.
Gomez-PeraltaFChoudharyPCossonEIraceCRami-MerharBSeiboldA. Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin. Diabetes Obes Metab. 2022;24(4):599-608. https://onlinelibrary.wiley.com/doi/10.1111/dom.14638. Accessed August 21, 2022.
41.
CacciatoreLCozzolinoGGiardinaMG, et al. Abnormalities of glucose metabolism induced by liver cirrhosis and glycosylated hemoglobin levels in chronic liver disease. Diabetes Res. 1988;7(4):185-188.
42.
KandaTNakamuraMIwasakiMWadaMKurotobiMShimizuY. Clinical significance of HbA1c, serum fructosamine and 1,5-AG in diabetic patients complicated with liver cirrhosis. J Japan Diabetes Soc. 1993;36:847-854.
43.
KuenenJCBorgRKuikDJ, et al. Does glucose variability influence the relationship between mean plasma glucose and HbA 1c levels in type 1 and type 2 diabetic patients?Diabetes Care. 2011;34(8):1843-1847. http://care.diabetesjournals.org/lookup/doi/10.2337/dc10-2217. Accessed February 17, 2019.
44.
LiuHYangDDengH, et al. Impacts of glycemic variability on the relationship between glucose management indicator from iPro™2 and laboratory hemoglobin A1c in adult patients with type 1 diabetes mellitus. Ther Adv Endocrinol Metab. 2020;11:2042018820931664. Published 2020 June 8. http://journals.sagepub.com/doi/10.1177/2042018820931664. Accessed August 25, 2022.
45.
BarronCVMHeenanHFThompsonHChanHNguJLuntH. Detecting dysglycaemia in compensated liver cirrhosis: comparison of oral glucose tolerance test and glycated haemoglobin, with continuous glucose monitoring. Diabet Med. 2022;3939(3):e14778. https://onlinelibrary.wiley.com/doi/10.1111/dme.14778. Accessed August 26, 2022.
46.
AddepallyNSGeorgeNMartinez-MaciasRGarcia-Saenz-de-SiciliaMKimWRDuarte-RojoA. Hemoglobin A1c has suboptimal performance to diagnose and monitor diabetes mellitus in patients with cirrhosis. Dig Dis Sci. 2018;63(12):3498-3508. http://link.springer.com/10.1007/s10620-018-5265-3. Accessed February 22, 2019.
47.
HondaFHiramatsuAHyogoH, et al. Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring. PLoS ONE. 2018;13(4):e0195028. https://dx.plos.org/10.1371/journal.pone.0195028. Accessed February 16, 2019.
48.
OgawaYNakaharaTOnoM, et al. Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease. J Gastroenterol Hepatol. 2022;37(3):592-599. https://onlinelibrary.wiley.com/doi/10.1111/jgh.15766. Accessed August 31, 2022.
49.
PerlmanJEGooleyTAMcNultyBMeyersJHirschIB. HbA1c and glucose management indicator discordance: a real-world analysis. Diabetes Technol Ther. 2021;23(4):253-258. https://www.liebertpub.com/doi/10.1089/dia.2020.0501. Accessed August 22, 2022.
50.
OriotPViryCVandelaerA, et al. Discordance between glycated hemoglobin A1c and the glucose management indicator in people with diabetes and chronic kidney disease. J Diabetes Sci Technol. 2022;17(6):1553–1562. http://journals.sagepub.com/doi/10.1177/19322968221092050. Accessed August 22, 2022.
CostaDLourençoJMonteiroAM, et al. Clinical performance of flash glucose monitoring system in patients with liver cirrhosis and diabetes mellitus. Sci Rep. 2020;10(1):7460. http://www.nature.com/articles/s41598-020-64141-x. Accessed June 25, 2022.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
